Hubbry Logo
Lipid profileLipid profileMain
Open search
Lipid profile
Community hub
Lipid profile
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Lipid profile
Lipid profile
Lipid profile
View on Wikipedia
from Wikipedia

Lipid profile
MeSH-
MedlinePlus003491
eMedicine-
LOINC24331-1, 57698-3

A lipid profile or lipid panel is a panel of blood tests used to find abnormalities in blood lipid ( such as cholesterol and triglycerides) concentrations.[not verified in body] The results of this test can identify certain genetic diseases and can determine approximate risks for cardiovascular disease, certain forms of pancreatitis, and other diseases.

Lipid panels are usually ordered as part of a physical exam, along with other panels such as the complete blood count (CBC) and basic metabolic panel (BMP).[not verified in body]

Components

[edit]

A lipid profile report typically includes:[1]

LDL is not usually actually measured, but calculated from the other three using the Friedewald equation.[1] A laboratory can optionally calculate the two extra values from the report:

Procedure and indication

[edit]

Recommendations for cholesterol testing come from the Adult Treatment Panel (ATP) III guidelines, and are based on many large clinical studies, such as the Framingham Heart Study.[citation needed]

For healthy adults with no cardiovascular risk factors, the ATP III guidelines recommend screening once every five years.[2] A lipid profile may also be ordered at regular intervals to evaluate the success of lipid-lowering drugs such as statins.[citation needed]

In the pediatric and adolescent population, lipid testing is not routinely performed. However, the American Academy of Pediatrics and the National Heart, Lung, and Blood Institute (NHLBI) recommend that children aged 9–11 be screened once for severe cholesterol abnormalities.[3] This screening can be valuable to detect genetic diseases such as familial hypercholesterolemia that can be lethal if not treated early.[citation needed]

Traditionally, most laboratories have required patients to fast for 9–12 hours before screening. However, studies have questioned the utility of fasting before lipid panels, and some diagnostic labs routinely accept non-fasting samples.[4][5][6][7]

Methods

[edit]

Friedewald

[edit]

Typically the laboratory measures only three quantities: total cholesterol; HDL; Triglycerides. A typical procedure used by NHANES 2004 uses the following measurement methods:[8]

  • Total cholesterol is measured using a mixture of enzymes. First an esterase converts cholesterol esters into cholesterol and free fatty acid. Then an oxidase oxidizes the cholesterol, producing a H2O2 side-product that changes the color of a dye. The amount of oxidation can be precisely quantified by light absorbance at 500 nm.[8]
  • Triglyceride concentration is also measured using an enzyme mixture. A lipase releases glycerol from the molecules, which gets oxidized by another enzyme while producing H2O2. The same color-change follows.[8]
  • HDL is measured in two steps. First a special reagent is added to the serum that binds apoB-containing lipoprotein particles, shielding them from the enzymes in the next step. Then a mixture of PEGylated enzymes is added with dye. The chemical reaction is the same as the total cholesterol measurement, except that the enzymes are blocked from acting on non-HDL lipoproteins by the reagent and their own PEG tails.[8]

From these three data LDL may be calculated. According to Friedewald's equation:[9]

  • [LDL] = [Total cholesterol] − [HDL] − ⁠ [Triglycerides] /5⁠

Other calculations of LDL from those same three data have been proposed which yield some significantly different results.[10]

VLDL can be defined as the total cholesterol that is neither HDL nor LDL. With that definition, Friedewald's equation[9] yields:

  • [VLDL] = ⁠ [Triglycerides] /5⁠

The alternative calculations mentioned above may yield significantly different values for VLDL.

The Friedewald method is reasonably reliable for the majority of patients, but is notably inaccurate in patients with hypertriglyceridemia (> 400 mg/dL or 4.5 mmol/L). It also underestimates LDL-C in patients with low LDL-C (< 25 mg/dL or 0.6 mmol/L). It does not take into account intermediate-density lipoprotein.[1]

A "Martin/Hopkins" variation that takes into how triglycerides-to-VLDL ratio tends to vary with other parameters appears more reliable and accurate.[11][12][13]

All-direct

[edit]

Every part of the lipid panel can be measured directly using ultracentrifugation, which is the gold standard.[1] This type of measurement involves no errors from estimation and can also measure IDL-C and Lp(a)-C levels. Fully direct measurement is more costly, however.[14]

Laboratories may also use proprietrary tests for "direct chemical LDL-C" which require no prior separation by centrifugation. These tests are not yet standardized in US and Europe and lack validation.[13] A specific version of the test seems popular in Japan, however.[15] A number of other LDL-C determination methods have been used in the past or have been proposed for future use.[16]

Implications

[edit]
See also: LDL and HDL

This test is used to identify dyslipidemia (various disturbances of cholesterol and triglyceride levels), many forms of which are recognized risk factors for cardiovascular disease and rarely pancreatitis.

A total cholesterol reading can be used to assess an individual's risk for heart disease; however, it should not be relied upon as the only indicator. The individual components that make up total cholesterol reading—LDL, HDL, and VLDL—are also important in measuring risk.[citation needed]

For instance, someone's total cholesterol may be high, but this may be due to very high HDL ("good cholesterol") cholesterol levels,—which can help prevent heart disease (the test is mainly concerned with high LDL, or "bad cholesterol" levels). So, while a high total cholesterol level may help give an indication that there is a problem with cholesterol levels, the components that make up total cholesterol should also be measured.[citation needed]

Lipid Profiling in Diabetes Risk Prediction

[edit]

A study by King's College London identified a novel blood test using lipid profiling to predict diabetes risk in children. Researchers found that lipid molecules in blood plasma could serve as early indicators for metabolic diseases, including type 2 diabetes, liver disease, and heart complications, even independent of obesity levels.[17]

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Lipid profile

View on Grokipedia
from Grokipedia
A lipid profile, also known as a lipid panel or test, is a that measures the levels of specific in the bloodstream, including total , (HDL) , (LDL) (often calculated), triglycerides, and an estimate of very low-density lipoprotein (VLDL) . This test provides a snapshot of an individual's cardiovascular health by evaluating the balance of these fats, which play key roles in transporting and energy throughout the body. Elevated or imbalanced levels can contribute to the buildup of plaque in arteries (), increasing the risk of heart disease, heart attack, and stroke. The primary components of a lipid profile are interpreted as follows: total cholesterol represents the overall amount of cholesterol in the blood and is desirable below 200 mg/dL; LDL cholesterol, often called "bad" cholesterol, should be under 100 mg/dL for healthy individuals (optimal), with targets such as below 70 mg/dL for those at high risk or with existing heart conditions as higher levels promote plaque formation; HDL cholesterol, known as "good" cholesterol, is protective and optimal at 60 mg/dL or higher, with levels at least 40 mg/dL in men or 50 mg/dL in women to avoid low levels; triglycerides, a type of fat derived from diet and stored energy, should be less than 150 mg/dL to minimize cardiovascular risk; very low-density lipoprotein (VLDL) cholesterol, typically estimated as triglycerides divided by 5, should be less than 30 mg/dL. These desirable levels apply generally to adults aged 20 and older, with no significant further age-based variation for men in adulthood; for boys and individuals under 20, desirable levels are lower (e.g., total cholesterol less than 170 mg/dL, LDL less than 110 mg/dL, HDL more than 45 mg/dL). These values are general guidelines from major health organizations; actual ranges may vary by laboratory, age, sex, and individual risk factors, and personalized interpretation by a healthcare provider is recommended. Screening via lipid profile is recommended for all adults starting at age 20, with testing every 4 to 6 years for those at low risk, and more frequently for higher-risk groups including people with , , or family history of high . Preparation typically involves for 9 to 12 hours, during which only is allowed, followed by a simple blood draw from a in the arm. Abnormal results often prompt lifestyle interventions like diet modification, exercise, and , or pharmacological treatments such as statins to lower lipid levels and prevent complications.

Overview

Definition

A lipid profile, also known as a lipid panel, is a panel that measures the concentrations of key in the bloodstream, including fractions and triglycerides, to detect potential abnormalities associated with cardiovascular risk. This diagnostic tool provides a snapshot of by quantifying total , high-density lipoprotein (HDL) , low-density lipoprotein (LDL) , and triglycerides from a single blood sample. The lipid profile evolved from early 20th-century basic tests, with significant advancements occurring in the mid-20th century through the development of enzymatic assays. These assays, first introduced for measurement in the early 1970s, enabled precise quantification and were standardized for clinical use in the 1970s, supplanting prior chemical methods and facilitating widespread adoption in routine laboratory practice. In contrast to full lipidomics analysis, which uses mass spectrometry to comprehensively profile hundreds of lipid species for research into metabolic pathways, the lipid profile targets only established clinical markers for practical diagnostic purposes.

Clinical Purpose

The lipid profile serves as a critical screening tool for assessing (CVD) risk in clinical practice, by evaluating levels of total , low-density lipoprotein (LDL-C), (HDL-C), and triglycerides, which contribute to and plaque buildup in arteries. Elevated LDL-C and triglycerides, along with low HDL-C, are established predictors of , heart attack, and , enabling early intervention through lifestyle modifications or . Additionally, it screens for acute risks such as , particularly when triglycerides exceed 500 mg/dL (5.6 mmol/L), and identifies genetic disorders like (FH), where LDL-C levels often surpass 190 mg/dL in untreated cases, prompting cascade screening in families. In line with updated guidelines, the 2018 American Heart Association (AHA)/American College of Cardiology (ACC) recommendations advocate universal lipid screening for all adults aged 20 years and older using either or nonfasting profiles, with repeat testing every 4 to 6 years for those at low 10-year atherosclerotic CVD (ASCVD) risk, and more frequent intervals (e.g., annually) for higher-risk individuals based on factors like , , or family history. This approach integrates the Pooled Cohort Equations for precise risk stratification in adults 40 to 75 years, facilitating shared decision-making on statin therapy. In contrast, the 2002 Adult Treatment Panel III (ATP III) guidelines from the National Cholesterol Education Program recommended lipoprotein profiles every 5 years for adults over 20, with less emphasis on lifetime risk assessment or nonfasting options. Lipid profiles are routinely combined with other standard tests, such as the (CBC) or (CMP), during annual wellness examinations to holistically evaluate metabolic health, detect comorbidities, and guide preventive care. Abnormalities in lipid levels, such as , further inform CVD risk but are interpreted alongside components detailed elsewhere.

Components

Total Cholesterol

Total cholesterol represents the overall concentration of in the , comprising both free (unesterified) and cholesteryl esters transported via various . This measurement captures the aggregate content without distinguishing between lipoprotein carriers, providing a foundational assessment of lipid status in clinical evaluations. In laboratory settings, total is quantified using an enzymatic colorimetric as the reference method, where cholesteryl esters are first hydrolyzed to free and then oxidized by to generate , which reacts to produce a quantifiable color change. This is widely adopted for its accuracy, precision, and automation compatibility in routine lipid profiling. As a , total serves as an indicator of the body's overall cholesterol load and is associated with risk, with elevated levels (typically above 200 mg/dL) signaling potential hypercholesterolemia. However, its interpretive value is limited compared to fractionated analyses, as it does not isolate protective or atherogenic components. Total also contributes to the calculation of low-density lipoprotein cholesterol via the Friedewald equation.

High-Density Lipoprotein Cholesterol

High-density lipoprotein (HDL) is a type of characterized by its high density and elevated protein content, primarily consisting of apolipoproteins such as apoA-I, which constitutes about 70% of its protein mass. These particles are small, discoidal or spherical in shape, with a core of cholesteryl esters and triglycerides surrounded by a monolayer and apolipoproteins that facilitate binding and transport. Unlike other lipoproteins, HDL has a lower -to-protein ratio, enabling its role in mobilization from peripheral tissues. The primary function of HDL is reverse cholesterol transport, wherein it acquires free from macrophages and other cells in arterial walls via the ATP-binding cassette transporter A1 (), esterifies it through lecithin-cholesterol acyltransferase (LCAT), and delivers it to the liver for excretion or recycling. This process helps prevent the accumulation of in atherosclerotic plaques, thereby exerting anti-atherogenic effects. HDL also exhibits , , and properties that contribute to vascular protection. HDL cholesterol is typically measured in clinical laboratories using either precipitation methods, where non-HDL lipoproteins are selectively precipitated with agents like or phosphotungstate to isolate HDL for enzymatic quantification, or direct homogeneous enzymatic assays that employ detergents to selectively solubilize HDL without . These methods ensure accurate determination of HDL-C levels, which are reported in milligrams per deciliter (mg/dL) as part of a standard lipid profile. Clinically, HDL cholesterol is often referred to as "good" cholesterol due to its inverse association with (CVD) risk, with higher levels generally conferring protection against and . According to guidelines from the National Cholesterol Education Program, HDL-C levels below 40 mg/dL in men and 50 mg/dL in women are considered low and represent a major risk factor for CVD, increasing the likelihood of atherosclerotic events. HDL-C contributes to the overall assessment of total but is evaluated independently for its protective implications.

Low-Density Lipoprotein Cholesterol

Low-density lipoprotein (LDL) particles, often referred to as "bad ," serve as the primary carriers of from the liver to peripheral tissues throughout the body. These spherical lipoproteins consist of a hydrophobic core rich in cholesteryl esters and triglycerides, surrounded by a hydrophilic shell of phospholipids, free , and one molecule of B-100 (ApoB-100), which facilitates receptor-mediated uptake by cells. While essential for delivering needed for synthesis and production, LDL particles are atherogenic due to their tendency to infiltrate the arterial intima, where they can undergo oxidative modification. Oxidation of LDL, triggered by reactive oxygen species in the vascular wall, transforms these particles into pro-inflammatory forms that promote , monocyte recruitment, and formation, key steps in atherosclerotic plaque development. Oxidized LDL (ox-LDL) is particularly damaging because it is recognized by scavenger receptors on macrophages, leading to unchecked uptake and lipid-laden cells that contribute to plaque buildup and arterial narrowing. This process underlies the causal link between elevated LDL levels and increased risk of atherosclerotic (ASCVD). In clinical practice, LDL cholesterol (LDL-C) is typically estimated indirectly using equations based on total cholesterol, HDL-C, and levels, but this approach is unreliable when triglycerides exceed 400 mg/dL, as it overestimates or underestimates LDL-C in such cases. Direct homogeneous assays, which involve enzymatic reactions to selectively measure LDL particles, offer greater accuracy in hypertriglyceridemic patients by avoiding interference from other lipoproteins. These methods, though more costly, are recommended when calculated values are suspect to ensure precise . According to guidelines from the (AHA) and (ACC), optimal LDL-C levels for adults without ASCVD are below 100 mg/dL, with even lower targets (e.g., <70 mg/dL) for those at high risk to mitigate atherosclerosis progression. Elevated LDL-C concentrations directly correlate with the extent of coronary atherosclerosis, as demonstrated in imaging and epidemiological studies, emphasizing the need for aggressive lowering in prevention strategies. LDL-C constitutes the majority of total cholesterol in most individuals.

Triglycerides

Triglycerides are chemical compounds consisting of a glycerol molecule esterified with three fatty acid chains, forming the primary form of fat storage in adipose tissue and the main lipid component of dietary fats. These molecules serve as an efficient energy reserve, releasing fatty acids when needed for metabolism, and are transported in the bloodstream primarily within lipoproteins. In lipid profile testing, triglycerides are quantified through an enzymatic assay that begins with hydrolysis by microbial lipase to liberate glycerol and free fatty acids from the serum sample. The freed glycerol then undergoes sequential reactions catalyzed by glycerokinase, glycerophosphate oxidase, and peroxidase, producing a colored quinoneimine dye whose absorbance is measured spectrophotometrically at 500 nm, with intensity proportional to triglyceride concentration. This method ensures high specificity by including a blanking step to account for endogenous glycerol in the sample. Elevated fasting triglyceride levels exceeding 150 mg/dL constitute one of the diagnostic criteria for metabolic syndrome, a cluster of conditions increasing the risk of cardiovascular disease, diabetes, and stroke. Extremely high levels above 1000 mg/dL, known as severe hypertriglyceridemia, significantly elevate the risk of acute pancreatitis, potentially leading to life-threatening inflammation of the pancreas. Triglycerides form the predominant lipid in very low-density lipoproteins (VLDL), facilitating their transport from the liver to peripheral tissues.

Very Low-Density Lipoprotein

Very low-density lipoprotein (VLDL) is a large, triglyceride-rich lipoprotein particle synthesized primarily in the liver, consisting of approximately 90% lipids and 10% proteins by composition. Its lipid core is dominated by triglycerides (about 70%), with smaller amounts of cholesterol esters and free fatty acids, while the surface includes phospholipids and apolipoproteins such as apo B-100 (the structural protein), apo C-I, C-II, C-III, and apo E. With a density range of 0.96–1.006 g/mL, VLDL particles are less dense than other lipoproteins due to their high triglyceride content. Hepatocytes assemble VLDL particles using apo B-100 as the scaffold, facilitated by microsomal triglyceride transfer protein (MTTP), which loads triglycerides and cholesterol esters onto the nascent particle. Once secreted into the bloodstream, VLDL matures by acquiring additional apolipoproteins (C-II and E) from high-density lipoprotein (HDL). VLDL serves as the primary vehicle for transporting endogenous triglycerides synthesized in the liver to peripheral tissues, including adipose, cardiac, and skeletal muscle, where apo C-II activates lipoprotein lipase (LPL) to hydrolyze triglycerides and release free fatty acids for energy or storage. As VLDL circulates, it progressively loses triglycerides through LPL action, transforming into intermediate-density lipoprotein (IDL); approximately half of IDL is cleared by the liver, while the remainder is further processed by hepatic lipase to remove apo E and additional lipids, ultimately converting to low-density lipoprotein (LDL). VLDL is not routinely measured directly in clinical lipid profiles due to the technical challenges of ultracentrifugation; instead, it is estimated indirectly as one-fifth of the fasting triglyceride concentration in mg/dL (VLDL cholesterol ≈ triglycerides/5), an approximation valid primarily when triglycerides are below 400 mg/dL. This estimation assumes a fixed ratio of triglycerides to cholesterol in VLDL particles, though it becomes less accurate in hypertriglyceridemic states. Elevated VLDL levels are closely associated with insulin resistance, a condition that impairs hepatic insulin signaling and increases free fatty acid flux to the liver, thereby boosting VLDL-triglyceride secretion by 3–5 times compared to insulin-sensitive states. This overproduction contributes to hypertriglyceridemia and hepatic steatosis, hallmarks of metabolic syndrome. Furthermore, high VLDL promotes the formation of small, dense LDL particles through lipid exchange with HDL, enhancing their atherogenic potential by increasing arterial retention and oxidative susceptibility, thus elevating cardiovascular disease risk.

Testing Procedures

Indications

A lipid profile test is recommended for routine screening in adults aged 20 years and older every 4 to 6 years to assess cardiovascular risk, with more frequent testing for individuals at higher risk, such as those with a family history of premature cardiovascular disease (CVD), diabetes, hypertension, obesity, or smoking. The 2018 American College of Cardiology/American Heart Association (ACC/AHA) guideline emphasizes this approach to identify dyslipidemia early, particularly in adults aged 40 to 75 years where 10-year atherosclerotic CVD (ASCVD) risk assessment guides further evaluation and management. For high-risk groups, such as those with familial hypercholesterolemia or existing CVD, testing may be performed annually or as clinically indicated to monitor progression and response to interventions. Specific indications for a lipid profile include the presence of symptoms suggestive of dyslipidemia, such as xanthomas (yellowish cholesterol deposits on the skin), xanthelasmas (around the eyelids), or corneal arcus in younger individuals, which warrant immediate testing to diagnose underlying lipid disorders. Monitoring statin or other lipid-lowering therapy is another key indication, with the ACC/AHA guideline recommending repeat profiles 4 to 12 weeks after initiating or intensifying treatment, and periodically thereafter to evaluate efficacy and adherence. In pregnancy, lipid profile testing is indicated for women with pre-existing dyslipidemia or additional CVD risk factors, as physiologic changes can exacerbate hyperlipidemia, though routine screening is not advised for all pregnant individuals. Post-menopausal women, who experience hormonal shifts increasing CVD risk, should undergo testing as part of enhanced adult screening protocols, often with greater frequency if other risk factors are present. For pediatric populations, universal lipid screening is recommended once between ages 9 and 11 years using a non-fasting non-HDL cholesterol measurement, with repeat screening between 17 and 21 years to detect early dyslipidemia. The American Academy of Pediatrics (AAP) guidelines advise earlier and more frequent testing for children with a family history of premature CVD or hypercholesterolemia, starting as young as 2 years in high-risk cases, to enable timely intervention and prevent long-term atherosclerotic complications.

Sample Collection

Sample collection for a lipid profile typically involves a venous blood draw, with specific preparation guidelines to ensure accurate results. Traditionally, patients are advised to fast for 9 to 12 hours prior to the test, consuming only water, to minimize postprandial effects on triglyceride levels and allow for reliable calculation of other lipid components. However, according to the 2016 European Atherosclerosis Society (EAS) consensus, non-fasting samples are acceptable and recommended for initial screening in most routine cases, as they improve patient compliance without significantly compromising cardiovascular risk assessment. Fasting remains necessary for precise evaluation in patients with suspected or confirmed hypertriglyceridemia, particularly if non-fasting triglycerides exceed 5 mmol/L (approximately 443 mg/dL), to avoid underestimation of low-density lipoprotein cholesterol. The procedure begins with venipuncture from a vein in the arm, using a standard needle to collect blood into a serum separator tube, such as a red-top or gold-top tube containing a clot activator. The tube is gently inverted several times immediately after collection to ensure proper mixing, and the sample is then centrifuged within 45 minutes to separate serum from cellular components, preventing hemolysis or lipemia that could interfere with analysis. Plasma may be used as an alternative if anticoagulants like heparin are added, but serum is preferred for most lipid assays due to its stability. Patients should receive pre-test instructions to optimize result reliability, including avoiding alcohol consumption for at least 24 hours beforehand, as it can transiently elevate triglycerides and alter lipid profiles. Additionally, lipid levels exhibit diurnal variation, with triglycerides typically higher in the evening due to cumulative dietary intake throughout the day, underscoring the preference for morning collections when possible.80016-3/pdf) These steps align with clinical indications for testing, such as routine cardiovascular risk screening in adults over 20 years.

Analytical Methods

Friedewald Equation

The Friedewald equation is a widely used method for estimating low-density lipoprotein cholesterol (LDL-C) levels from a standard lipid panel, avoiding the need for direct measurement via ultracentrifugation. Developed in 1972 by William T. Friedewald, Robert I. Levy, and Donald S. Fredrickson, it provides a practical approach for clinical assessment of cardiovascular risk based on plasma lipid concentrations. The formula is expressed as: LDL-C=Total cholesterol−HDL-C−(Triglycerides5)\text{LDL-C} = \text{Total cholesterol} - \text{HDL-C} - \left( \frac{\text{Triglycerides}}{5} \right) where all values are in mg/dL. This calculation assumes that very low-density lipoprotein (VLDL) cholesterol constitutes approximately 20% of triglyceride levels, hence the division by 5 to estimate VLDL-C, which is subtracted from non-HDL cholesterol to isolate LDL-C. Despite its simplicity and broad adoption, the Friedewald equation has notable limitations that can affect its accuracy. It becomes unreliable when triglyceride levels exceed 400 mg/dL, as the fixed ratio assumption fails under such hypertriglyceridemia. Additionally, it is inaccurate in type III hyperlipoproteinemia due to abnormal lipoprotein compositions that invalidate the VLDL estimation. The equation also tends to underestimate LDL-C in patients with low LDL-C levels, particularly below 100 mg/dL, leading to potential misclassification of risk in certain populations.

Martin-Hopkins Method

The Martin-Hopkins method represents an advancement in estimating low-density lipoprotein cholesterol (LDL-C) from standard lipid panel measurements, addressing limitations of earlier calculations by using a dynamic adjustment for variability in lipoprotein composition. Developed to improve precision in diverse patient populations, it replaces the fixed division factor in prior equations with one tailored to individual lipid profiles. This approach enhances reliability for cardiovascular risk assessment, particularly in scenarios where traditional methods falter, such as elevated triglycerides or low LDL-C levels. The core formula for the Martin-Hopkins method is: LDL-C=Total cholesterol−HDL-C−(Triglyceridesvariable factor)\text{LDL-C} = \text{Total cholesterol} - \text{HDL-C} - \left( \frac{\text{Triglycerides}}{\text{variable factor}} \right) The variable factor, which estimates the triglyceride-to-very low-density lipoprotein cholesterol (VLDL-C) ratio, is derived from a lookup table stratified by triglyceride levels (typically in ranges from <100 mg/dL to 300–399 mg/dL) and non-HDL cholesterol concentrations (from <100 mg/dL to >220 mg/dL), yielding values generally between 3 and 11 to better reflect empirical ratios observed in large datasets. This adjustability allows for more personalized estimation compared to fixed-ratio approaches. The method originated from a validation study analyzing over 1.1 million patients' profiles against directly measured LDL-C via ultracentrifugation, revealing 10–20% greater accuracy across broader ranges (up to 400 mg/dL) and improved into guideline-based categories, with the novel correctly categorizing LDL-C in 91.3% of cases versus 85.7% for the Friedewald . An extended version, validated in subsequent research, applies similar adjustable factors for triglycerides up to 800 mg/dL, achieving up to 62% accuracy in hypertriglyceridemic samples where other methods drop below 20%. These improvements stem from accounting for the non-constant triglyceride-VLDL-C ratio, which varies with metabolic conditions. Key advantages include robust performance with non-fasting samples, reducing logistical burdens for patients, and applicability in routine panels without specialized assays. The 2018 AHA/ACC guidelines endorse the Martin-Hopkins method over the Friedewald equation for LDL-C estimation, particularly when triglycerides exceed 150 mg/dL or LDL-C is below 70 mg/dL, to support more precise statin therapy decisions and atherosclerotic cardiovascular disease risk evaluation.

Sampson-NIH Equation

The Sampson-NIH equation is a 2020 advancement for estimating low-density lipoprotein cholesterol (LDL-C) from standard lipid panels, designed for improved accuracy in patients with triglyceride levels up to 800 mg/dL. Developed by researchers at the National Institutes of Health, it incorporates adjustments for non-HDL cholesterol and triglycerides to better account for VLDL variability, validated against beta-quantification (ultracentrifugation reference). The formula is: LDL-C=Total cholesterol0.948−HDL-C0.971−(Triglycerides8.56+Triglycerides×(Total cholesterol−HDL-C)2140−Triglycerides216,905)\text{LDL-C} = \frac{\text{Total cholesterol}}{0.948} - \frac{\text{HDL-C}}{0.971} - \left( \frac{\text{Triglycerides}}{8.56} + \frac{\text{Triglycerides} \times (\text{Total cholesterol} - \text{HDL-C})}{2140} - \frac{\text{Triglycerides}^{2}}{16{,}905} \right) where all values are in mg/dL. This equation outperforms the Friedewald in low LDL-C scenarios and , with studies showing higher concordance (e.g., 89-92% accurate classification) compared to direct assays in diverse populations, including non-fasting samples. Validated in datasets exceeding patients, it demonstrates mean absolute differences under 10 mg/dL versus reference methods, reducing misclassification risk by 15-25% over Friedewald. As of 2023, literature (e.g., ) recommends it as a preferred alternative to Martin-Hopkins for certain profiles, such as or , aligning with ongoing guideline evolutions for precise risk assessment.

Direct LDL Measurement

Direct measurement of cholesterol (LDL-C) involves laboratory techniques that quantify LDL particles without relying on indirect calculations from other fractions. These methods are particularly valuable in scenarios where estimation formulas, such as those detailed in other analytical approaches, become unreliable, like when levels exceed 400 mg/dL. The primary direct methods include ultracentrifugation, considered the gold standard for its precision in separating classes, and homogeneous enzymatic assays, which are more commonly used in clinical settings due to . Ultracentrifugation employs gradient separation to isolate LDL, followed by quantification, providing high accuracy by distinguishing LDL from (IDL) and lipoprotein(a). Homogeneous enzymatic assays represent the most widely adopted direct approach for routine testing. These assays use detergents and enzymes to block interference from (HDL) and (VLDL), allowing selective enzymatic reaction with LDL cholesterol. Developed in the and refined for autoanalyzers, examples include the Kyowa Medex and Denka Seiken methods, which offer rapid results without extensive . However, they can exhibit biases of up to 13-46% in patients with dyslipidemias due to variable lipoprotein compositions. In terms of accuracy, direct methods generally align with ultracentrifugation reference procedures within a total error of 12% or less for non-diseased individuals, with biases ranging from -6.8% to 1.1% and coefficients of variation under 4%. For diseased populations, performance may degrade, with total errors up to 31.9%, highlighting the need for method validation in specific clinical contexts. Applications extend to research settings for detailed lipoprotein profiling and clinical cases requiring precise LDL-C values, such as or non-fasting samples. Direct assays are 2-3 times more costly than calculated estimates due to specialized reagents and equipment, limiting their routine use but justifying them for high-stakes assessments. Advanced direct techniques, such as (NMR) , provide additional insights beyond content by measuring LDL particle number and size distribution. NMR analyzes proton signals from methyl groups to quantify particles, revealing small, dense LDL subtypes associated with elevated cardiovascular risk. This method, while not a direct measure, complements enzymatic assays in evaluations but requires expensive infrastructure.

Interpretation

Reference Ranges

Reference ranges for lipid profile components provide benchmarks for assessing cardiovascular health, derived from major clinical guidelines that classify levels as optimal, borderline, or high risk based on population studies and outcomes data. These ranges are general guidelines for healthy adults and may vary by laboratory, age, sex, and individual risk factors. Higher-risk individuals may require stricter targets. It is essential to consult a healthcare provider for personalized interpretation. Lipid profile results are commonly reported in milligrams per deciliter (mg/dL) in the United States and some other regions, while millimoles per liter (mmol/L) is standard in many other countries. Standard conversion factors from mmol/L to mg/dL are: multiply values for total cholesterol, HDL cholesterol, and LDL cholesterol by 38.67; multiply triglyceride values by 88.57. For example, 3.5 mmol/L total cholesterol equals approximately 135 mg/dL, and 1.9 mmol/L triglycerides equals approximately 168 mg/dL. These conversions align with the equivalent values provided in guidelines and elsewhere in this article. For healthy adults aged 20 years and older, general desirable ranges for lipid profile components (in mg/dL) according to major health organizations are:
  • Total cholesterol: Less than 200 (desirable)
  • Triglycerides: Less than 150 (desirable/normal)
  • HDL cholesterol: 60 or higher (optimal/best); at least 40 (men) or 50 (women) to avoid low levels
  • LDL cholesterol: Less than 100 (optimal for healthy individuals; lower targets like <70 for high-risk)
  • VLDL cholesterol: Less than 30 (often estimated as triglycerides divided by 5)
For men aged 20 years and older, desirable levels do not vary significantly by age once adulthood is reached, with consistent recommendations across major health organizations (including the American Heart Association and National Heart, Lung, and Blood Institute) showing no further age-based differentiation beyond age 20. These include total cholesterol less than 200 mg/dL, LDL cholesterol less than 100 mg/dL (optimal), HDL cholesterol 40 mg/dL or higher (ideally 60 mg/dL or higher), and triglycerides less than 150 mg/dL. For adults, the (AHA) and (ACC) 2018 guidelines establish the following desirable levels: total below 200 mg/dL, low-density lipoprotein (LDL-C) below 100 mg/dL, high-density lipoprotein (HDL-C) at or above 60 mg/dL (with levels below 40 mg/dL in men or 50 mg/dL in women considered low), and triglycerides below 150 mg/dL. Levels between these thresholds and higher cutoffs (e.g., total 200-239 mg/dL as borderline) indicate increasing risk, guiding preventive interventions. The 2025 focused update of the 2019 (ESC) and European Atherosclerosis Society (EAS) guidelines emphasize risk-stratified targets but align with general ranges such as LDL-C below 116 mg/dL (3 mmol/L) for low-risk individuals, while recommending stricter goals like below 70 mg/dL for high-risk groups to reduce atherosclerotic (ASCVD) events.
ComponentOptimal/Desirable (mg/dL)Borderline (mg/dL)High Risk (mg/dL)
Total <200200-239≥240
LDL-C<100100-129≥130
HDL-C (Men)≥6040-59<40
HDL-C (Women)≥6050-59<50
Triglycerides<150150-199≥200
These adult benchmarks show gender-specific differences, particularly for HDL-C, where women typically maintain higher levels (e.g., mean around 55-60 mg/dL versus 45-50 mg/dL in men) due to estrogen influences, leading to adjusted low thresholds. In pediatric populations (ages 2-19 years), reference ranges are generally lower to reflect developmental norms and lower ASCVD risk; for example, the National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend total cholesterol below 170 mg/dL, LDL-C below 110 mg/dL, HDL-C above 45 mg/dL, and triglycerides below 90 mg/dL for ages 10-19 (or below 75 mg/dL for ages 0-9) as acceptable levels. These lower ranges apply to children and adolescents under 20 years of age, including boys under 20. Age-specific adjustments account for pubertal changes, with borderline LDL-C at 110-129 mg/dL and high at 130 mg/dL or above signaling need for evaluation. Modern guidelines, such as the 2025 ESC/EAS update, also recommend considering non-HDL cholesterol (calculated as total cholesterol minus HDL-C; desirable <130 mg/dL in adults) for enhanced risk assessment in both adults and children.

Influencing Factors

Several lifestyle factors significantly influence lipid profile components, including diet, physical activity, and smoking. A diet high in saturated fatty acids, found in foods such as butter, red meat, and full-fat dairy, elevates low-density lipoprotein cholesterol (LDL-C) levels by promoting hepatic cholesterol synthesis and reducing LDL receptor activity. Regular aerobic exercise, such as brisk walking or cycling for at least 150 minutes per week, increases high-density lipoprotein cholesterol (HDL-C) by enhancing reverse cholesterol transport and lipoprotein lipase activity. Cigarette smoking lowers HDL-C concentrations by approximately 4-6 mg/dL through oxidative stress and inhibition of hepatic HDL production, while also contributing to overall dyslipidemia. Physiological variables like age, gender, and pregnancy also modulate lipid levels. LDL-C and total cholesterol typically rise with age, particularly after 40 years, due to decreased clearance and increased production in both sexes, with men showing a steeper increase up to 64% in LDL-C from ages 20 to 49. Premenopausal women generally exhibit a more favorable profile with lower triglycerides compared to men, attributed to estrogen's protective effects on lipid metabolism, though this reverses post-menopause as triglycerides equalize or exceed male levels. During pregnancy, total cholesterol and triglycerides increase progressively, often by 25-50% in the third trimester, driven by hormonal changes including elevated estrogen and progesterone that stimulate hepatic lipid synthesis to support fetal development. Pathological conditions and certain medications can further alter lipid profiles. Hypothyroidism elevates LDL-C by reducing LDL receptor expression and impairing thyroid hormone-mediated lipid clearance, often leading to hypercholesterolemia that resolves with thyroxine replacement. Nephrotic syndrome causes marked hypercholesterolemia through urinary loss of regulatory proteins like lipoprotein lipase, resulting in elevated total cholesterol and LDL-C levels that correlate with proteinuria severity. Beta-blockers, commonly used for hypertension, increase triglycerides by 10-40% via inhibition of lipolysis and reduced hepatic LDL receptor activity, while slightly decreasing HDL-C, though vasodilating subtypes have milder effects.

Clinical Implications

Cardiovascular Disease Risk

The lipid profile plays a central role in assessing and predicting the risk of atherosclerotic cardiovascular disease (ASCVD), which encompasses coronary heart disease, stroke, and peripheral artery disease. Non-high-density lipoprotein (non-HDL) cholesterol, calculated as total cholesterol minus HDL cholesterol, serves as a superior predictor of ASCVD risk compared to LDL cholesterol alone because it captures the atherogenic potential of all apoB-containing lipoproteins, including LDL and VLDL remnants. This metric integrates seamlessly into the ASCVD risk estimator, such as the Pooled Cohort Equations, which calculate a 10-year risk score based on factors including age, sex, race, total cholesterol, HDL cholesterol, blood pressure, diabetes status, and smoking. Elevated LDL cholesterol promotes the buildup of atherosclerotic plaques by facilitating the infiltration of cholesterol into arterial walls, leading to inflammation, foam cell formation, and progressive narrowing of blood vessels. Conversely, low HDL cholesterol impairs reverse cholesterol transport, the process by which HDL particles remove excess cholesterol from peripheral tissues and deliver it to the liver for excretion, thereby exacerbating plaque accumulation and increasing ASCVD vulnerability. These mechanisms underscore the clinical implications of lipid profile abnormalities, guiding therapeutic decisions such as statin initiation for individuals with a 10-year ASCVD risk exceeding 7.5%, where moderate- to high-intensity statins are recommended to mitigate risk. The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol marks a shift toward emphasizing percent reductions in LDL cholesterol—aiming for at least 30% in intermediate-risk patients (7.5% to <20% 10-year risk) and 50% or more in high-risk cases—over rigid absolute targets, as the magnitude of reduction correlates more directly with ASCVD event reduction. This approach prioritizes achievable outcomes from maximally tolerated statin therapy, with non-HDL cholesterol monitored as a secondary target to ensure comprehensive atherogenic lipoprotein control. Incomplete control of non-HDL cholesterol after statin therapy confers ongoing cardiovascular risk, even in patients who achieve LDL cholesterol targets. For instance, in statin-treated patients with ischemic heart disease and well-controlled LDL-C (≤1.8 mmol/L), elevated non-HDL-C levels (≥2.7 mmol/L) were associated with a 1.8-fold increased risk of ASCVD events compared to levels in the 25th–74th percentile. Similarly, among individuals with diabetes or chronic kidney disease initiating statins for primary prevention, having LDL-C below threshold but non-HDL-C above threshold was linked to higher rates of adverse cardiovascular outcomes, with a hazard ratio of 1.16. These findings underscore the importance of monitoring non-HDL-C to address residual risk beyond LDL-C goals.

Diabetes Risk Prediction

Lipid profiles play a key role in identifying prediabetes and susceptibility to type 2 diabetes through specific markers associated with insulin resistance and metabolic dysfunction. High triglycerides (≥150 mg/dL) and low high-density lipoprotein (HDL) cholesterol (<40 mg/dL in men or <50 mg/dL in women) are established components of the metabolic syndrome criteria, which collectively elevate the risk of developing type 2 diabetes by promoting insulin resistance and impaired glucose metabolism. The triglyceride-to-HDL cholesterol (TG/HDL-C) ratio serves as a particularly useful surrogate marker, with values exceeding 3.5 indicating significant insulin resistance and a heightened susceptibility to type 2 diabetes, independent of other factors like body mass index. This ratio reflects underlying dyslipidemia tied to glycemic dysregulation, offering a simple, non-invasive indicator for early intervention. Predictive models incorporating lipid indices have demonstrated enhanced stratification of diabetes risk across age groups. In the Framingham Offspring Study, a cohort of middle-aged adults, inclusion of lipid parameters such as low HDL cholesterol and elevated triglycerides in a simple clinical risk model yielded an area under the receiver operating characteristic curve (AROC) of 0.85 for predicting incident type 2 diabetes over 8 years, comparable to more complex models without substantial additional benefit from advanced measures like insulin levels. Advanced lipid profiling, including triacylglycerol signatures from the same study, further refines prediction by identifying insulin resistance patterns. In pediatric populations, the TG/HDL-C ratio ≥2.0 has been shown to increase the odds of insulin resistance by 3- to 58-fold in nonobese children, enabling better risk categorization for prediabetes in youth. The American Diabetes Association (ADA) guidelines emphasize the role of lipid profiling in screening for diabetes risk among high-risk youth. For children and adolescents who are overweight (BMI ≥85th percentile) or obese, with additional risk factors such as family history of diabetes, screening for type 2 diabetes is recommended starting at age 10 years or puberty onset, where lipid profiles contribute to assessing metabolic risk alongside glucose testing. Initial lipid evaluation is advised soon after diabetes diagnosis in youth aged ≥2 years, once glycemia stabilizes, to guide management of dyslipidemia linked to glycemic control. Non-fasting lipid profiles are sufficient and preferable for initial diabetes risk assessment, as they provide reliable insights into triglyceride and HDL levels without the inconvenience or hypoglycemia risk associated with fasting, particularly in diabetic individuals.

Other Associated Conditions

Severe hypertriglyceridemia, defined as triglyceride levels exceeding 1000 mg/dL, is a well-established cause of acute pancreatitis, ranking as the third most common etiology after gallstones and alcohol. This condition, known as hypertriglyceridemic pancreatitis, arises from the toxic effects of free fatty acids generated by lipolysis of circulating triglycerides within pancreatic tissue, leading to inflammation and potential necrosis. The risk escalates significantly above this threshold, with studies estimating a 10-20% incidence of acute pancreatitis in affected individuals. Management typically involves immediate triglyceride-lowering interventions, such as fibrates to enhance lipoprotein lipase activity or plasmapheresis for rapid removal of chylomicrons in refractory cases, alongside supportive care like fasting and insulin therapy if needed. Genetic disorders like familial hypercholesterolemia (FH) manifest prominently in lipid profiles through markedly elevated low-density lipoprotein cholesterol (LDL-C) levels, often exceeding 190 mg/dL in untreated adults with the heterozygous form. FH results from mutations in genes such as LDLR, APOB, or , impairing LDL clearance and leading to premature atherosclerosis, though diagnosis extends beyond lipids to include clinical criteria like tendon xanthomas and family history, confirmed by genetic testing. In homozygous FH, LDL-C can surpass 500 mg/dL, necessitating aggressive therapies including high-intensity statins, ezetimibe, and PCSK9 inhibitors to mitigate complications. Lipid profiling thus serves as an initial screening tool, guiding referral for confirmatory genetic analysis. Non-alcoholic fatty liver disease (NAFLD) is frequently associated with dyslipidemia characterized by elevated triglycerides and reduced high-density lipoprotein cholesterol (HDL-C), reflecting hepatic triglyceride accumulation that exceeds 5% of hepatocytes. This lipid imbalance contributes to steatosis progression, with hypertriglyceridemia promoting very low-density lipoprotein (VLDL) overproduction and insulin resistance. While not diagnostic in isolation, an abnormal lipid profile supports NAFLD evaluation alongside imaging and liver enzymes. Lipoprotein(a) [Lp(a)], though measured separately from standard lipid panels, emerges as a relevant marker in lipid-related genetic conditions, with elevated levels (>50 mg/dL) indicating inherited risk independent of other . In contexts like FH, high Lp(a) exacerbates thrombotic tendencies, underscoring its role in comprehensive assessment.

References

  1. https://www.mayoclinic.org/tests-procedures/cholesterol-test/about/pac-20384601
  2. https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/what-your-cholesterol-levels-mean
  3. https://www.cdc.gov/cholesterol/testing/index.html
  4. https://my.clevelandclinic.org/health/articles/24540-vldl-cholesterol
  5. https://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=90&ContentID=P01593
  6. https://medlineplus.gov/ency/article/007812.htm
  7. https://my.clevelandclinic.org/health/diagnostics/17176-lipid-panel
  8. https://www.ncbi.nlm.nih.gov/books/NBK355892/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC11560336/
  10. https://www.kcl.ac.uk/open-global/biomarkers/emerging-biomarkers/lipid-profiling-and-lipidomics
  11. https://portlandpress.com/biochemist/article/44/1/20/230687/A-beginner-s-guide-to-lipidomics
  12. https://www.ahajournals.org/doi/10.1161/cir.0000000000000625
  13. https://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf
  14. https://www.ncbi.nlm.nih.gov/books/NBK351/
  15. https://www.ncbi.nlm.nih.gov/books/NBK305896/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9296199/
  17. https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2021/DataFiles/TCHOL_L.htm
  18. https://www.ncbi.nlm.nih.gov/books/NBK333647/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC4138905/
  20. https://www.ncbi.nlm.nih.gov/books/NBK549802/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3215094/
  22. https://www.ahajournals.org/doi/10.1161/circresaha.114.300935
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6509080/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7199822/
  25. https://www.cdc.gov/cholesterol/about/index.html
  26. https://www.ahajournals.org/doi/10.1161/01.cir.0000126889.97626.b8
  27. https://academic.oup.com/eurheartj/article/41/24/2313/5735221
  28. https://www.sciencedirect.com/science/article/abs/pii/S1388198100001232
  29. https://www.ncbi.nlm.nih.gov/books/NBK343489/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3315351/
  31. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785570
  32. https://www.sciencedirect.com/science/article/abs/pii/S0009898125004863
  33. https://jcp.bmj.com/content/76/3/145
  34. https://www.acc.org/Latest-in-Cardiology/Articles/2025/07/01/01/Prioritizing-Health-Dietary-Approaches-For-Elevated-LDL-C
  35. https://www.nhlbi.nih.gov/health/high-blood-triglycerides
  36. https://wwwn.cdc.gov/nchs/data/nhanes/public/2003/labmethods/l13_c_met_lipids.pdf
  37. https://www.ncbi.nlm.nih.gov/books/NBK459248/
  38. https://www.ncbi.nlm.nih.gov/books/NBK459368/
  39. https://www.nlm.nih.gov/medlineplus/ency/article/003494.htm
  40. https://www.ncbi.nlm.nih.gov/books/NBK587400/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC4226221/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3163828/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC11871407/
  44. https://www.ncbi.nlm.nih.gov/books/NBK542294/
  45. https://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/cholesterol-disorders/overview-of-cholesterol-and-lipid-disorders
  46. https://www.ncbi.nlm.nih.gov/books/NBK498654/
  47. https://publications.aap.org/pediatrics/article/130/2/353/81649/Guidelines-for-Lipid-Screening-in-Children-and
  48. https://academic.oup.com/eurheartj/article/37/25/1944/1749006
  49. https://www.labcorp.com/tests/303756/lipid-panel
  50. https://www.dshs.texas.gov/laboratory-services/laboratory-services-section-testing-services/lipid-panel
  51. https://myhealth.alberta.ca/Health/tests-treatments/Pages/conditions.aspx?hwid=hw207814
  52. https://pubmed.ncbi.nlm.nih.gov/4337382/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC4159084/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC11903449/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC10289049/
  56. https://pubmed.ncbi.nlm.nih.gov/32101259/
  57. https://academic.oup.com/clinchem/article/70/2/399/7450974
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC9768618/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4687457/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC10961624/
  61. https://www.ahajournals.org/doi/10.1161/circulationaha.108.816181
  62. https://my.clevelandclinic.org/health/articles/11920-cholesterol-numbers-what-do-they-mean
  63. https://www.ncbi.nlm.nih.gov/books/NBK83505/
  64. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Focused-Update-on-Dyslipidaemias
  65. https://www.ahajournals.org/doi/10.1161/01.ATV.17.12.3513
  66. https://www.nhlbi.nih.gov/files/docs/guidelines/peds_guidelines_full.pdf
  67. https://www.ncbi.nlm.nih.gov/books/NBK570127/
  68. https://www.ncbi.nlm.nih.gov/books/NBK326737/
  69. https://pubmed.ncbi.nlm.nih.gov/23852759/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4383267/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC8072568/
  72. https://www.ncbi.nlm.nih.gov/books/NBK588296/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC8551734/
  74. https://www.ncbi.nlm.nih.gov/books/NBK559182/
  75. https://www.ncbi.nlm.nih.gov/books/NBK326739/
  76. https://www.ahajournals.org/doi/10.1161/atvbaha.116.307601
  77. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.119.312617
  78. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00193-X/fulltext
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC12418469/
  80. https://my.clevelandclinic.org/health/diseases/10783-metabolic-syndrome
  81. https://www.ahajournals.org/doi/10.1161/01.cir.0000089506.12223.f1
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC10375356/
  83. https://www.sciencedirect.com/science/article/pii/S0022227520353050
  84. https://pubmed.ncbi.nlm.nih.gov/17533210/
  85. https://www.jci.org/articles/view/44442
  86. https://diabetesjournals.org/care/article/35/1/158/27320/Usefulness-of-the-High-Triglyceride-to-HDL
  87. https://diabetesjournals.org/care/article/48/Supplement_1/S283/157559/14-Children-and-Adolescents-Standards-of-Care-in
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC6232011/
  89. https://www.jacc.org/doi/10.1016/j.jacc.2017.08.006
  90. https://www.ncbi.nlm.nih.gov/books/NBK279082/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC9652119/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC8330650/
  93. https://www.mayoclinic.org/diseases-conditions/familial-hypercholesterolemia/diagnosis-treatment/drc-20353757
  94. https://www.ncbi.nlm.nih.gov/books/NBK556009/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC10065162/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC5471681/
Add your contribution
Related Hubs
User Avatar
No comments yet.